Table of Contents
344 million people live with dry eye disease, and most treatments lubricate symptoms instead of fixing the damaged collagen behind them.
Stuart Therapeutics is testing the first collagen mimetic peptide for dry eye disease, with relief reported in 2 to 4 days.
ST-100 (vezocolmitide) reported Phase 3 data in June 2025. It did not reach statistical significance on the Schirmer's tear primary endpoint, but produced Week 1 fluorescein staining gains vs. vehicle greater than any approved dry eye therapy on record. Stuart now plans to engage the FDA on a follow-on Phase 3, while advancing PolyCol™ variants for glaucoma (licensed to Glaukos) and dry AMD.
At JPM 2026, Onyx sat down with President & CEO, Eric Schlumpf, to find out more.
A special thanks to our Onyx Live sponsors:
HUMPHREYS LAW – a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/
Panacea – AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
Comments